<DOC>
	<DOC>NCT00201851</DOC>
	<brief_summary>This trial tests surgical oophorectomy (removal of ovaries) plus Tamoxifen, done at different times in the menstrual cycle, as adjuvant therapy for invasive breast cancer in 510 premenopausal women with Hormone Receptor-positive Breast Cancer. This study is recruiting at hospitals in Philippines, Vietnam, and Morocco.</brief_summary>
	<brief_title>Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Open for accrual in Asia only Female age 1850, premenopausal with regular cycles (&gt;2535 in length) fineneedle aspiration diagnosis Stage IIIIIA hormone receptor positive invasive breast cancer No prior radiation or chemotherapy Must be surgical candidate for bilateral oophorectomy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Asian</keyword>
	<keyword>Premenopausal</keyword>
	<keyword>Women</keyword>
	<keyword>Oophorectomy</keyword>
</DOC>